Autoantibody-negative but probable pediatric autoimmune encephalitis following COVID-19 vaccination: A case report

Ando, Makoto; Matsunami, Kunihiro; Yuzawa, Sotaro; Sakashita, Tatsuya; Murakami, Hiroaki; Kuwabara, Shuji; Matsukuma, Eiji; Imamura, Atsushi

doi:10.1016/j.nerep.2023.100173

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Since the implementation of COVID-19 vaccines in children, several AEs have been detected in postauthorization safety monitoring. [6][7][8][9][10] These include encephalitis, 11 nephritis, 12 neurological complications, 13 and myocarditis. 14 Vaccines may have non-specific (off-target) effects, i.e., an ability to affect the risk of other diseases by either reducing or increasing the susceptibility to other infections.…”

Section: Meaningmentioning

confidence: 99%

See 1 more Smart Citation

Overall Health Effects of mRNA COVID-19 Vaccines in Children and Adolescents A Systematic Review and Meta-Analysis

Hoffmann,

Nielsen,

Thysen

et al. 2023

Preprint

View full text Add to dashboard Cite

ImportancePhase 3 randomized controlled trials (RCTs) of mRNA COVID-19 vaccines in children and adolescents showed efficacy in preventing COVID-19 infections. Vaccines may have non-specific effects which are not assessed within the current regulatory framework.ObjectiveConduct a systematic review and meta-analysis of the phase 3 trials to assess overall and non-specific health effects of the mRNA COVID-19 vaccines in children.Data SourcesPubMed, Embase, Clinical Trials, Web of Science, and regulatory websites were searched for RCTs of mRNA vaccines. The latest trial data was included.Study SelectionAll RCTs conducted with mRNA vaccines BNT162b2 and mRNA-1237 in children and adolescents below 18 years of age, with placebo, adjuvant, or other vaccines as controls. Two authors independently screened 1199 studies, six were included in the analysis.Data Extraction and SynthesisData on serious adverse events (SAEs) and severe adverse events (AEs) as well as organ-specific diseases was extracted following the PRISMA reporting guideline, with a focus on non-specific infectious events. Risk Ratios (RRs) comparing vaccine and placebo cohorts were calculated separately for each vaccine and combined in Mantel-Haenszel estimates.Main Outcomes and MeasuresThe primary outcome was SAEs -- overall and infectious. Secondary outcomes were severe AEs and lower respiratory tract infection (LRTI) including RSV.ResultsThe analyses included 25,549 individuals (17,538 mRNA vaccine recipients and 8,011 placebo recipients). The risk of SAEs were similar for vaccine and placebo recipients. Both mRNA vaccines were associated with increased risk of severe AEs in older children. In a combined analysis, the RR was 3.77 (1.56-9.13[0.4% vs 0.1% in vaccine vs placebo recipients]) in above 5 year-olds, and 0.82 (0.53-1.29)[0.8% vs 0.9%])in younger children (p=0.003 for same effect in older and younger children). In the younger children, mRNA vaccines were associated with higher risk of LRTI (3.03 (1.29-7.09) [0.6% vs 0.2%]).Conclusions and RelevancemRNA vaccines did not increase the risk of SAEs but were associated with an increased risk of severe AEs in older children, and an increased risk of LRTI in the young. Further research into the overall and non-specific health effects of mRNA vaccines is warranted.Question, Findings, and MeaningQuestionWhat is the overall health effect of mRNA COVID-19 vaccines in children?FindingsIn this systematic review and meta-analysis of phase 3 trials, mRNA vaccine vs. placebo was not associated with increased risk of serious adverse events. The mRNA vaccines were associated with higher risk of severe adverse events in children aged 5 years and older. In children younger than 5 years, mRNA vaccines were associated with a 3-fold higher risk of lower respiratory tract infections.MeaningDespite the low risk of adverse events, the results suggest that mRNA vaccines increase the risk of severe adverse events. However, given the low risk of COVID-19 infection in children, this is relevant to consider. The results suggest that mRNA vaccines are associated with increased risk of severe adverse events and increased risk of LRTI. Given the low risk of severe COVID-19 infection in children, it is not clear that the benefit of COVID-19 vaccines in children outweigh the harms.

show abstract

Section: Meaningmentioning

confidence: 99%

“…Since the implementation of COVID-19 vaccines in children, several AEs have been detected in post-authorization safety monitoring. 6–10 These include encephalitis, 11 nephritis, 12 neurological complications, 13 and myocarditis. 14…”

Section: Introductionmentioning

confidence: 99%